The potential of deferasirox as a novel therapeutic modality in gastric cancer

about

Alterations in Cellular Iron Metabolism Provide More Therapeutic Opportunities for Cancer.

P2860

Q55497286-4B147DB0-373C-4C32-AD74-1AD7411A4BC2

P2860

The potential of deferasirox as a novel therapeutic modality in gastric cancer

Item

http://www.wikidata.org/entity/Q38787167

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

The potential of deferasirox as a novel therapeutic modality in gastric cancer

@en

type

Item

label

The potential of deferasirox as a novel therapeutic modality in gastric cancer

@en

prefLabel

The potential of deferasirox as a novel therapeutic modality in gastric cancer

@en

P1476

The potential of deferasirox as a novel therapeutic modality in gastric cancer

@en

P2093

Byeong Bae Park

http://www.w3.org/2001/XMLSchema#string

Jieun Uhm

http://www.w3.org/2001/XMLSchema#string

Jung Hye Choi

http://www.w3.org/2001/XMLSchema#string

Jung Soon Kim

http://www.w3.org/2001/XMLSchema#string

Young Yiul Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer

Structure, function, and mechanism of ribonucleotide reductases.

Iron and colorectal cancer risk: human studies.

The Drg-1 gene suppresses tumor metastasis in prostate cancer.

Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2011.

Iron and cancer: more ore to be mined.

The Haber-Weiss reaction and mechanisms of toxicity.

Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging

A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.

P2888

s12957-016-0829-1

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12957-016-0829-1

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Young-Woong Won

P577

2016-03-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

297753432

http://www.w3.org/2001/XMLSchema#string

P6179

1000055045

http://www.w3.org/2001/XMLSchema#string

P698

26965928

http://www.w3.org/2001/XMLSchema#string

P932

4785730

http://www.w3.org/2001/XMLSchema#string

The potential of deferasirox as a novel therapeutic modality in gastric cancer

about

P2860

P2860

The potential of deferasirox as a novel therapeutic modality in gastric cancer

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P50

P577

P5875

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P50

P577

P5875

P6179

P698

P932